AstraZeneca has halted its planned £200m Cambridge research site expansion, stalling its entire £650m UK investment package.
The project was expected to create 1,000 jobs but now joins a scrapped £450m vaccine facility in Merseyside.
The company recently pledged $50bn US investment by 2030, funding drug plants and labs across several states.
The pause follows Merck’s cancellation of a £1bn London research hub and Eli Lilly’s suspended £279m gateway lab.
Industry leaders warn the UK is losing appeal as drugmakers face high costs and disputes over NHS pricing policies.
Sanofi said Britain is “not a good place” for life sciences without a clear Treasury-backed plan for competitiveness.
AstraZeneca Pauses £200m Cambridge Expansion Amid Wider UK Pharma Setbacks
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
